Study finds potential treatment for drug-resistant H7N9 influenza virus

The novel avian H7N9 influenza virus has caused more than 130 human infections with 43 deaths in China. New research, conducted under the supervision of Kansas State University's Juergen Richt, is showing promise in helping to fight this deadly virus.

"Emergence of a novel drug-resistant H7N9 : Evidence-based clinical potential of a natural IFN-alpha for infection control and treatment" is set to publish in an early online edition of January's Expert Review of Anti-infective Therapy journal.

Richt is a regents distinguished professor and Kansas Bioscience Authority eminent scholar at Kansas State University's College of Veterinary Medicine. He also is the director of the U.S. Department of Homeland Security's Center of Excellence for Emerging and Zoonotic Animal Diseases, or CEEZAD, at the university. The center is working with scientists at Hemispherx Biopharma Inc. to develop novel pharmacological treatments. Research for the H7N9 project was conducted at the university's Biosecurity Research Institute, primarily by Qinfang Liu, a postdoctoral fellow in diagnostic medicine and pathobiology in Richt's laboratory.

Richt is recognized as an expert on zoonotic agents and has published extensively on the monitoring of mutations and basic events leading to cross-species transmission of influenza viruses and the opportunities to adapt to human hosts, with the potential to cause a pandemic. Because of the lack of existing immunity against H7 subtype influenza viruses in the human population and the absence of a licensed commercial vaccine, antiviral drugs are critical tools for the treatment of with this novel H7N9.

"Both M2-ion channel blockers, such as amantadine, and neuraminidase inhibitors, such as Tamiflu or Relenza, are used as for influenza infections of humans," Richt said. "The emerging H7N9 viruses are resistant to the M2-ion channel blockers and some also to neuramidinidase inhibitors because of mutations in the respective viral proteins. In this study we report that Alferon N can inhibit wild type and Tamiflu-resistant H7N9 virus replication in vitro. Since Alferon N is approved for clinical use, this would allow a rapid regulatory approval process for this drug under pandemic threat."

The research was partially funded by the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health in the Department of Health and Human Services; the Department of Homeland Security; and Hemispherx Biopharma.

CEEZAD, officially inaugurated in June 2010, enhances the capability of the Department of Homeland Security by developing state-of-the-art countermeasures for high priority emerging and zoonotic animal diseases. Richt also a professor of diagnostic medicine and pathobiology at Kansas State University's College of Veterinary Medicine.

Related Stories

Resistant flu virus keeps contagiousness

Dec 10, 2013

A mutant form of the H7N9 flu virus that is resistant to frontline drugs is just as contagious as its non-resistant counterpart, according to a lab test reported on Tuesday.

Recommended for you

Ebola kills 31 people in DR Congo: WHO

46 minutes ago

An outbreak of the Ebola virus in the Democratic Republic of Congo has killed 31 people and the epidemic remains contained in a remote northwestern region, UN the World Health Organization (WHO) said Tuesday.

Dengue fever strikes models in Japan

3 hours ago

A worsening outbreak of dengue fever in Japan has claimed its first celebrities—two young models sent on assignment to the Tokyo park believed to be its source.

Japanese researchers develop 30-minute Ebola test

3 hours ago

Japanese researchers said Tuesday they had developed a new method to detect the presence of the Ebola virus in 30 minutes, with technology that could allow doctors to quickly diagnose infection.

Senegal monitors contacts of 1st Ebola patient

15 hours ago

Senegalese authorities on Monday were monitoring everyone who was in contact with a student infected with Ebola who crossed into the country, and who has lost three family members to the disease.

Cerebral palsy may be hereditary

21 hours ago

Cerebral palsy is a neurological developmental disorder which follows an injury to the immature brain before, during or after birth. The resulting condition affects the child's ability to move and in some ...

User comments